Covid 19 Vaccine: Wockhardt partners with RDIF to produce, supply Sputnik vaccine
Drug maker Wockhardt on Friday said it has inked a pact with the Russian Direct Investment Fund (RDIF) to produce and supply COVID-19 vaccines -- Sputnik V and Sputnik Light.
Drug maker Wockhardt on Friday said it has inked a pact with the Russian Direct Investment Fund (RDIF) to produce and supply COVID-19 vaccines -- Sputnik V and Sputnik Light.
The agreement has been inked under the aegis of Enso Healthcare (part of Enso Group), RDIF's coordination partner for sourcing Sputnik V vaccines in India.
See Zee Business Live TV Streaming Below:
"We are delighted to partner with RDIF to make a substantial contribution towards providing global supply of the Sputnik V and Sputnik Light vaccines which is one of the most efficacious approved vaccines commercially available," Wockhardt Group Founder Chairman Habil Khorakiwala said in a statement.
The arrangement upholds the company's ongoing commitment to fight against such a pandemic of global human importance, he added.
It is our privilege to partner with RDIF and Wockhardt to facilitate large scale manufacturing of Sputnik V and Sputnik Light vaccines," Enso Healthcare Chairman Vinay Maloo noted.
In a regulatory filing, Wockhardt noted that subject to requisite approvals and other conditions, the company would manufacture and supply up to 620 million doses of the Sputnik V and the Sputnik Light vaccines to Enso.
The term of the agreement is up to June 2023, it added.
Till date, the Sputnik V vaccine has been registered in 69 countries globally with a total population of over 3.7 billion people.
The data obtained by regulators of a number of countries during the vaccination of the population, including Argentina, Serbia, Bahrain, Hungary, Mexico, San Marino, UAE and others, demonstrates that Sputnik V is one of the safest and most effective vaccines against coronavirus.
In particular, Sputnik V demonstrates 83.1 per cent efficacy against the Delta variant of coronavirus - higher than many other vaccines.
The vaccine is based on a well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
Sputnik Light is the first component of Sputnik V and is based on human adenovirus serotype 26.
Wockhardt shares were trading 4.92 per cent up at Rs 513.35 apiece on BSE.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Power of Compounding: How many years will it take to reach Rs 3 crore corpus if your monthly SIP is Rs 4,000, Rs 5,000, or Rs 6,000
IRCTC Dividend 2024: Railway PSU announces 200% interim dividend - Check record date and other details
Power of Compounding: Salary Rs 25,000 per month; is it possible to create over Rs 2.60 crore corpus; understand it through calculations
Reduce Home Loan EMI vs Reduce Tenure: Rs 75 lakh, 25-year loan; which option can save Rs 25 lakh and 64 months and how? Know here
Top 7 Large and Mid Cap Mutual Funds with Best SIP Returns in 5 Years: No. 1 fund has turned Rs 15,000 monthly SIP investment into Rs 20,54,384; know about others
New Year Pick by Anil Singhvi: This smallcap stock can offer up to 75% return in long term - Check targets
PSU Oil Stocks: Here's what brokerage suggests on these 2 largecap, 1 midcap scrips - Buy, Sell or Hold?
03:46 PM IST